NASDAQ · ETNB
Healthcare · Biotechnology
$14.84
Up+$0.00 (+0.00%)
Updated Sep 9, 2026, 5:19 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ETNB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ETNB.
ETNB research
Company profile and research snapshot.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 19, 2025 | Raymond James | Market Perform | — |
| Sep 19, 2025 | Wolfe Research | Peer Perform | — |
| Sep 19, 2025 | HC Wainwright & Co. | Neutral | — |
| Aug 25, 2025 | B of A Securities | Buy | — |
| Aug 8, 2025 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
seekingalpha.com · Oct 28, 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ETNB.
No results
No recent SID articles mention ETNB.
